Abstract

The increasing complexity in the early development phase led to a booming demand for sophisticated CRO/CDMO partners. In order to seize these emerging opportunities, NUVISAN has been fastly developing its capabilities and capacities since 2010 through different acquisitions and partnerships in Europe.

In July 2020, NUVISAN acquired large parts of Bayer's Berlin-based small molecule research unit to expand its portfolio of services.

Want to know how this expanded portfolio can better assist you?

How can you benefit from our top-notch expertise in early pharmaceutical research at the INNOVATION CAMPUS BERLIN (ICB)?

Join this webinar as our CEO, Dr Dietrich Bruchmann and COO, Dr Hans Lindner, expose their view on NUVISAN integrated services from research to early clinical phase and how its full-fledged research unit in Berlin can better assist you.

In this 45-minute presentation, we'll cover:

• NUVISAN's wide range of services: from research to early clinical stage (Phase II).
• Expansion of NUVISAN's portfolio with new small molecules drug discovery capabilities and capacities acquired from Bayer.
• Live Q&A session